KIT
DreaMed's GlucoSitter technology has
just gained CE accreditation, although
it will not be commercially available for
a while. Based on an artificial pancreas
algorithm, GlucoSitter is intended to
integrate within an insulin pump or be
operated via a dedicated handheld
device. It uses input data from a CGM the
sensor worn by the diabetic and analyzes
it, then commands the pump to deliver
the correct dose of insulin (and at the
right time). By monitoring glucose levels
around the clock, it can precisely define
when and how to adjust insulin levels.
DreaMed Diabetes was established
in 2014 to commercialize the company's
closed-loop solution for patients with T1
and T2 diabetes. The company states,
"We understand clinical practice and
strive to close the gap between patients
and their optimal glycemic control. Our
vision is to create a viable solution that
empowers insulin dependent patients
to make the right decisions on how to
handle their diabetes control."
www.dreamed-diabetes.com
DREAM SOLUTION
SYSTEMS ADDICTS...
For more on technology that talks, see our feature on p.10.